Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment
Neal Shore, MD, FACS, explains how he integrates findings from the ARAMIS trial to inform patient treatment decisions while prioritizing patient values and personal preferences.
EP: 1.Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case
EP: 2.Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC
EP: 3.Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC
EP: 4.Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment
EP: 5.Addressing Unmet Needs and Final Perspectives on nmCRPC
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
